Radiant

Radiant Biotherapeutics is a preclinical-stage biotechnology company developing a novel class of multivalent, multi-specific antibody therapeutics. Utilizing its proprietary Multibody platform, the company engineers molecules with high valency and flexibility, enabling them to bind to multiple targets or epitopes simultaneously with exceptional potency. This approach is designed to overcome the limitations of traditional monoclonal antibodies in treating complex diseases like cancer and chronic infectious diseases. Radiant's lead research focuses on oncology and virology, supported by significant investment from venture capital firms and global health organizations. The company's technology originated from research at The Hospital for Sick Children and the University of Toronto.